AN2 Therapeutics, Inc.
ANTX
$1.26
-$0.02-1.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 40.99% | 11.69% | 13.13% | 1.66% | -1.14% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.59% | -15.21% | 6.72% | 39.74% | -39.44% |
| Change in Net Operating Assets | 340.37% | 67.59% | 41.41% | -107.12% | -132.45% |
| Cash from Operations | 56.08% | 16.53% | 18.24% | -3.08% | -44.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -136.75% | 13.72% | -37.39% | 6,159.52% | 100.67% |
| Cash from Investing | -136.75% | 13.72% | -37.39% | 6,159.52% | 100.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -100.00% | 208.72% | -100.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -280.45% | 224.42% | -77.05% | 153.31% | -107.04% |